Zura Bio Ltd

Zura Bio is a clinical-stage biotechnology company focused on developing therapies for individuals suffering from autoimmune and inflammatory disorders. The company’s pipeline comprises three licensed drug candidates: tibulizumab, a bispecific antibody designed to inhibit both IL-17A and BAFF; crebankitug, a monoclonal antibody targeting IL-7 receptor alpha; and torudokimab, a monoclonal antibody directed against IL-33. Rather than serving commercial customers, the firm evaluates its experimental treatments in adult clinical trial participants, with tibulizumab undergoing evaluation for hidradenitis suppurativa and diffuse cutaneous systemic sclerosis.

The company operates without dedicated in-house facilities, instead relying on contract manufacturers across Italy, the Netherlands, and the United Kingdom, alongside stability studies in China, to produce drug substance and drug product batches. Clinical studies take place across the United States, Canada, Europe, and Latin America, involving over three hundred targeted participants across active Phase 2 programs. The provided text does not identify the location of the corporate headquarters.

Summary of the business section of Zura Bio's latest annual report, written by StockData.

“As of December 31, 2025, we had 40 full-time employees.”